Private equity firm Arcline Investment Management invested in Dark Horse Consulting Group, the leading global consultancy practice specializing in cell and gene therapy product development. Financial terms were not disclosed. Arcline commented, "Our partnership with Dark Horse demonstrates our commitment to the emerging regenerative medicine industry. We look forward to working closely with Dark Horse to solve critical industry-wide manufacturing bottlenecks, speeding patient access to these revolutionary therapies."